Non-invasive serum [as protein C-reactive protein (CRP)] and fecal inflammatory biomarkers [as fecal calprotectin (FC)] are useful for monitoring patients with IBD by regular measures throughout the patient’s disease course. Here, CRP is linked to inflammatory bowel disease.